SlideShare ist ein Scribd-Unternehmen logo
1 von 5
Downloaden Sie, um offline zu lesen
 
 
Balkrishna Industries 
Results above estimates; outlook encouraging
May 20, 2014 
PrabhudasLilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the 
Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision. 
Please refer to important disclosures and disclaimers at the end of the report 
 
Q4FY14 Result Update 
Surjit Arora 
surjitarora@plindia.com 
+91‐22‐66322235 
Hussain Kagzi 
hussainkagzi@plindia.com 
+91‐22‐66322242 
Rating  Accumulate 
Price  Rs568 
Target Price  Rs630 
 Implied Upside   10.9% 
Sensex   24,377 
Nifty  7,276 
(Prices as on May 20, 2014) 
Trading data 
Market Cap. (Rs bn)  54.9 
Shares o/s (m)  96.7 
3M Avg. Daily value (Rs m)  174.2 
Major shareholders 
Promoters  58.30% 
Foreign  11.00% 
Domestic Inst.  16.74% 
Public & Other   13.96% 
Stock Performance 
(%)  1M  6M  12M 
Absolute  12.2  100.8  109.3 
Relative   4.5  82.7  88.8 
How we differ from Consensus 
EPS (Rs)  PL  Cons.  % Diff. 
2015  57.6  56.1  2.7 
2016  66.3  64.1  3.4 
 
Price Performance (RIC: BLKI.BO, BB: BIL IN) 
 
Source: Bloomberg 
100
200
300
400
500
600
700
May‐13
Jul‐13
Sep‐13
Nov‐13
Jan‐14
Mar‐14
May‐14
(Rs)
Balkrishna  Industries  (BIL’s)  Q4FY14  operating  performance  was  better  than  our 
estimate on account of higher than expected volume growth at 19.8% during the 
quarter.  Strong  topline  led  to  a  450bps  YoY  improvement  in  EBITDA  margins  to 
25.8%  with  EBITDA  for  the  quarter  increasing  by  61.5%  YoY  to  Rs2.68bn  (PLe‐
Rs2.52bn). Given the strong balance sheet, with ROEs in excess of 20% and strong 
free  cash  flow  in  FY15E  and  FY16E,  we  maintain  our  ‘Accumulate’  rating  on  the 
stock. The stock is currently trading at 5.6x FY16E EV/EBITDA and 8.6x FY16E EPS, 
at a ~26% discount to Titan International. Given the superior ROEs and earnings 
CAGR of ~15.0%, we assign a 1yr fwd P/E multiple of 9.5x FY16E earnings (@ 20% 
discount to Titan International) to arrive at our TP of Rs630/share.     
 Adj.  Profit  grew  by  85.6%  YoY  led  by  strong  operational  performance:  BIL 
reported a growth of 33.0% in its top‐line at Rs10.4bn (PLe: Rs10.0bn), mainly 
on account of 19.8% increase in volume to 40,823 tonnes. Recipe cost/kg in the 
current quarter declined by 5.5% YoY to Rs118.5/kg on account of lower natural 
rubber cost. As a result, raw material/sales ratio declined by 800bps YoY. This 
was  partially  negated  by  390bps  YoY  increase  in  other  expenses.  As  a  result, 
EBITDA  margins  expanded  by  450bps  to  25.8%.  This  resulted  in  a  61.5%  YoY 
increase  in  EBITDA  to  Rs2.7bn  (PLe‐Rs2.5bn).  On  account  of  strong  operating 
performance,  PAT  grew  by  85.6%  YoY  to  Rs1.5bn  ahead  of  our  estimate  of 
Rs1.3bn. 
Contd…2 
 
   
Key financials (Y/e March)        2013 2014  2015E 2016E
Revenues (Rs m)  31,906 35,767  41,375 48,326
     Growth (%)  13.1 12.1  15.7 16.8
EBITDA (Rs m)  6,645 8,937  10,534 12,235
PAT (Rs m)  3,559 4,877  5,571 6,409
EPS (Rs)  36.8 50.5  57.6 66.3
     Growth (%)  32.5 37.0  14.2 15.0
Net DPS (Rs)  1.6 2.0  3.0 4.0
 
Profitability & Valuation        2013 2014  2015E 2016E
EBITDA margin (%)  20.8 25.0  25.5 25.3
RoE (%)  28.5 29.5  25.8 23.3
RoCE (%)  11.8 12.9  13.2 14.6
EV / sales (x)  2.3 2.2  1.8 1.4
EV / EBITDA (x)  11.0 8.9  7.2 5.6
PE (x)  15.4 11.3  9.9 8.6
P / BV (x)  3.9 2.9  2.3 1.8
Net dividend yield (%)  0.3 0.4  0.5 0.7
Source: Company Data; PL Research 
   
May 20, 2014  2
  Balkrishna Industries 
 Concall highlights – Refinancing of ECBs to save Rs100‐120m of interest cost: 
Management indicated refinancing of $100m ECB at LIBOR + 20bps, whereas the 
$175mn  ECB  has  been  refinanced  at  a  lower  rate  at  2.1‐2.2%  as  against  3% 
earlier. The above would lead to a savings in the interest cost to the tune of 
Rs100‐120m/ year. Management maintained its volume guidance of 160,000 – 
165,000  MT  for  FY15E  and  200,000  MT  for  FY16E.  Management  sounded 
positive  on  the  demand  outlook  for  both,  agricultural  as  well  as  industrial 
segment (construction and mining) across geographies.  
 Euro revenues hedged at Rs87/€ in FY15E as against Rs75/€ in FY14: BIL have 
locked in an average rate of Rs87/€ for FY15 as against Rs75/€ in FY14. Hence, 
the  recent  currency  appreciation  (Rs80/€)  would  not  have  any  impact  on  the 
profitability of the company. At the same time, on account of correction in the 
raw material prices (esp. Natural Rubber), they have taken a price cut of 4‐5% in 
Apr’14.  Despite  this,  management  sounded  confident  on  maintaining  the 
EBITDA  margins  at  25‐26%  range  as  they  would  enjoy  higher  realisations  on 
account of currency hedges. 
 Outlook  and  Valuation:  Balakrishna  Industries  (BIL)  has  built  a  substantive 
export  business  in  off‐highway‐tyres  (OHT),  a  niche  area,  where  it  enjoys  a 
global market share of ~4%. BKT generates 90% of its revenues from exports. By 
offering an extensive variety of OHTs (2,000+ SKUs) at prices 25‐30% lower than 
the  global  majors  (Michelin,  Bridgestone),  BKT  has  leveraged  India’s  low‐cost 
manufacturing  capabilities  to  a  great  effect.  Given  the  strong  balance  sheet, 
with ROEs in excess of 20% and strong free cash flow in FY15E and FY16E, we 
maintain our ‘Accumulate’ rating on the stock. The stock is currently trading at 
5.6x  FY16E  EV/EBITDA  and  8.6x  FY16E  EPS,  at  a  ~26%  discount  to  Titan 
International.  
 
   
May 20, 2014  3
  Balkrishna Industries 
Exhibit 1: Q4FY14 Result Overview (Rs m) 
Y/e March  Q4FY14 Q4FY13 YoY gr. (%) Q3FY14 FY14  FY13 YoY gr. (%)
Net Sales      10,306          7,740             (1.6)        8,673      35,357      31,731            11.4 
Other Operating Income              62                53          182.5            171            410            175          134.5 
Total      10,368          7,793            33.0         8,844      35,767      31,906            12.1 
Expenditure                
Raw Material          4,839          4,273          (12.9)        4,104      17,210      17,910             (3.9)
  % of Net Sales          46.9            55.2            47.3          48.7          56.4   
Salaries & Wages            407             314            55.9            360         1,386         1,075            28.9 
  % of Net Sales             3.9              4.1               4.2             3.9             3.4   
Power and Fuel            331             262              5.5           285         1,170         1,153              1.4 
  % of Net Sales             3.2              3.4               3.3             3.3             3.6   
Other Exp.         2,113          1,285          (11.4)        1,806         7,064         5,124            37.9 
  % of Net Sales          20.5            16.6            20.8          20.0          16.1   
Total Expenditure         7,690          6,134           6,555      26,830      25,262   
EBITDA         2,679          1,659            61.5         2,289         8,938         6,644            34.5 
  EBITDA Margin (%)          25.8            21.3            26.4          25.0          20.8   
Depreciation            479             321            49.0            425         1,650         1,077            53.2 
Net Exchange Difference (Gain)/Loss             (21)             (32)                 ‐              (5)              57   
Net interest              99                35          185.1              59            255            200            27.7 
Non Operative Income              31                11          193.4              52            138              42          229.5 
Exceptional                
PBT         2,153          1,345            60.0         1,857         7,175         5,352            34.1 
Tax Total            611             494            23.7            619         2,293         1,794            27.9 
  Tax Rate‐Total (%)  28.4 36.7   33.3 32.0  33.5  
Rep.PAT         1,542             851            81.1         1,238         4,882         3,558            37.2 
Extraordinary Expenses             (21)             (32)                 ‐              (5)              57   
Adj. profit         1,521             819            85.6         1,238         4,877         3,615            34.9 
Operating Metrics 
Sale Tonnage (MT)      40,823        34,061            19.9      33,901    142,810    138,339              3.2 
Realisation in Rs per Kg            254             227            11.8            261            250            231              8.6 
Recipe (RM) cost in Rs per Kg            119             125             (5.5)           121            121            129             (6.9)
EBITDA per kg              66                49            34.7              68              63              48            30.3 
Source: xxx 
   
   
May 20, 2014  4
  Balkrishna Industries 
Income Statement (Rs m)           
Y/e March       2013  2014  2015E 2016E
Net Revenue  31,906  35,767  41,375 48,326
Raw Material Expenses  17,910  17,210  20,256 23,770
Gross Profit  13,996  18,557  21,119 24,556
Employee Cost  1,075  1,386  1,597 1,831
Other Expenses  6,277  8,234  8,988 10,490
EBITDA  6,645  8,937  10,534 12,235
Depr. & Amortization  1,077  1,650  2,100 2,500
Net Interest  200  255  420 500
Other Income  42  138  300 330
Profit before Tax  5,410  7,170  8,314 9,565
Total Tax  1,794  2,293  2,744 3,156
Profit after Tax  3,617  4,877  5,571 6,409
Ex‐Od items / Min. Int.  (57)  10  — —
Adj. PAT  3,559  4,877  5,571 6,409
Avg. Shares O/S (m)  96.7  96.7  96.7 96.7
EPS (Rs.)  36.8  50.5  57.6 66.3
 
Cash Flow Abstract (Rs m)    
Y/e March       2013  2014  2015E 2016E
C/F from Operations  5,501  5,111  6,525 6,812
C/F from Investing  (9,594)  (7,277)  (2,000) (500)
C/F from Financing  3,181  (399)  (3,996) (3,606)
Inc. / Dec. in Cash  (911)  (2,564)  529 2,705
Opening Cash  3,574  2,663  99 627
Closing Cash  2,663  99  627 3,333
FCFF  (164)  1,256  1,522 3,316
FCFE  3,848  5,086  (1,978) (1,184)
 
 
 
Key Financial Metrics 
Y/e March       2013  2014  2015E 2016E
Growth     
Revenue (%)  13.1  12.1  15.7 16.8
EBITDA (%)  31.3  34.5  17.9 16.1
PAT (%)  32.5  37.0  14.2 15.0
EPS (%)  32.5  37.0  14.2 15.0
Profitability     
EBITDA Margin (%)  20.8  25.0  25.5 25.3
PAT Margin (%)  11.2  13.6  13.5 13.3
RoCE (%)  11.8  12.9  13.2 14.6
RoE (%)  28.5  29.5  25.8 23.3
Balance Sheet     
Net Debt : Equity  1.3  1.3  0.8 0.4
Net Wrkng Cap. (days)  78  89  79 80
Valuation     
PER (x)  15.4  11.3  9.9 8.6
P / B (x)  3.9  2.9  2.3 1.8
EV / EBITDA (x)  11.0  8.9  7.2 5.6
EV / Sales (x)  2.3  2.2  1.8 1.4
Earnings Quality     
Eff. Tax Rate  33.2  32.0  33.0 33.0
Other Inc / PBT  0.8  1.9  3.6 3.5
Eff. Depr. Rate (%)  6.0  7.6  8.0 8.2
FCFE / PAT  108.1  104.3  (35.5) (18.5)
Source: Company Data, PL Research. 
 
   
Balance Sheet Abstract (Rs m)   
Y/e March       2013  2014  2015E 2016E
Shareholder's Funds  14,190  18,826  24,304 30,602
Total Debt  20,744  24,574  21,074 16,574
Other Liabilities  999  1,000  1,100 1,100
Total Liabilities  35,932  44,400  46,478 48,276
Net Fixed Assets  22,232  28,058  27,958 25,458
Goodwill  —  —  — —
Investments  329  4,265  4,265 4,265
Net Current Assets  13,370  12,077  14,255 18,553
     Cash & Equivalents  2,663  98  628 3,333
     Other Current Assets  15,228  16,320  18,218 20,469
     Current Liabilities  4,520  4,341  4,591 5,249
Other Assets  —  —  — —
Total Assets  35,932  44,400  46,478 48,276
 
 
 
 
Quarterly Financials (Rs m)     
Y/e March      Q1FY14  Q2FY14  Q3FY14 Q4FY14
Net Revenue  8,159  8,396  8,844 10,368
EBITDA  1,787  2,024  2,289 2,679
% of revenue  21.9  24.1  25.9 25.8
Depr. & Amortization  353  393  425 479
Net Interest  (128)  5  7 68
Other Income  171  44  52 31
Profit before Tax  1,548  1,619  1,857 2,153
Total Tax  524  524  619 611
Profit after Tax  1,024  1,095  1,238 1,542
Adj. PAT  1,038  1,095  1,238 1,521
Source: Company Data, PL Research. 
 
   
May 20, 2014  5
  Balkrishna Industries 
 
 
 
 
 
Prabhudas Lilladher Pvt. Ltd. 
3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai‐400 018, India 
Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209 
Rating Distribution of Research Coverage   
26.2%
52.4%
21.4%
0.0%
0%
10%
20%
30%
40%
50%
60%
BUY Accumulate Reduce Sell
% of Total Coverage
 
PL’s Recommendation Nomenclature     
BUY   :  Over 15% Outperformance to Sensex over 12‐months  Accumulate  :  Outperformance to Sensex over 12‐months 
Reduce  :  Underperformance to Sensex over 12‐months  Sell  :  Over 15% underperformance to Sensex over 12‐months 
Trading Buy  :  Over 10% absolute upside in 1‐month  Trading Sell  :  Over 10% absolute decline in 1‐month 
Not Rated (NR)  :  No specific call on the stock  Under Review (UR)  :  Rating likely to change shortly 
This  document  has  been  prepared  by  the  Research  Division  of  Prabhudas  Lilladher  Pvt.  Ltd.  Mumbai,  India  (PL)  and  is  meant  for  use  by  the  recipient  only  as 
information and is not for circulation.  This document is not to be reported or copied or made available to others without prior permission of PL. It should not be 
considered or taken as an offer to sell or a solicitation to buy or sell any security. 
The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy 
or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information, 
statements and opinion given, made available or expressed herein or for any omission therein. 
Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The 
suitability  or  otherwise  of  any  investments  will  depend  upon  the  recipient's  particular  circumstances  and,  in  case  of  doubt,  advice  should  be  sought  from  an 
independent expert/advisor. 
Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or 
engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication. 
We may from time to time solicit or perform investment banking or other services for any company mentioned in this document. 

Weitere ähnliche Inhalte

Was ist angesagt?

Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15
IndiaNotes.com
 
Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15
IndiaNotes.com
 
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buyCrompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
IndiaNotes.com
 

Was ist angesagt? (18)

GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; HoldIndoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
Indoco Remedies: Weak domestic growth offsets export revenues in Q1FY16; Hold
 
Gandhi Special Tubes Limited
Gandhi Special Tubes Limited Gandhi Special Tubes Limited
Gandhi Special Tubes Limited
 
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacityApollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
Apollo Tyres approves further expansion of the Truck & Bus radial tyre capacity
 
1 rubber factory ah authors
1 rubber factory ah authors 1 rubber factory ah authors
1 rubber factory ah authors
 
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 Q3FY15 Recommendation: Maintain hold on Alembic Pharma Q3FY15 Recommendation: Maintain hold on Alembic Pharma
Q3FY15 Recommendation: Maintain hold on Alembic Pharma
 
Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15Firstcall metroglobal limited_13jul15
Firstcall metroglobal limited_13jul15
 
Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15Fce deepak nitrite_28jul15
Fce deepak nitrite_28jul15
 
Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410Buy DB Corp at a target of Rs410
Buy DB Corp at a target of Rs410
 
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters alsoVidhi Dyestuffs: To keep its growth story in the coming quarters also
Vidhi Dyestuffs: To keep its growth story in the coming quarters also
 
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buyCrompton Greaves 3QFY15 performance remains a mixed bag; buy
Crompton Greaves 3QFY15 performance remains a mixed bag; buy
 
AIA Engineering Q4FY15: Firstcall recommend for target of 1125
AIA Engineering Q4FY15: Firstcall recommend for target of 1125AIA Engineering Q4FY15: Firstcall recommend for target of 1125
AIA Engineering Q4FY15: Firstcall recommend for target of 1125
 
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
Buy Jenburkt Pharmaceuticals; government's amended FDI policy to cover medica...
 
Financial analysis assignment: Analyzing the Business Strategies of Various C...
Financial analysis assignment: Analyzing the Business Strategies of Various C...Financial analysis assignment: Analyzing the Business Strategies of Various C...
Financial analysis assignment: Analyzing the Business Strategies of Various C...
 
Presentation on Adamjee Insurance
Presentation on Adamjee Insurance Presentation on Adamjee Insurance
Presentation on Adamjee Insurance
 
QNBFS Weekly Market Report March 05, 2020
QNBFS Weekly Market Report March 05, 2020QNBFS Weekly Market Report March 05, 2020
QNBFS Weekly Market Report March 05, 2020
 
Buy Asian Paints, discussions going on with two states for new paint plants
Buy Asian Paints, discussions going on with two states for new paint plantsBuy Asian Paints, discussions going on with two states for new paint plants
Buy Asian Paints, discussions going on with two states for new paint plants
 
Pl shree cement_04may15[1]
Pl shree cement_04may15[1]Pl shree cement_04may15[1]
Pl shree cement_04may15[1]
 

Ähnlich wie Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas Lilladher

KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
IndiaNotes.com
 
Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610
Angel Broking
 
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceQ2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
IndiaNotes.com
 

Ähnlich wie Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas Lilladher (20)

Cipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15ECipla Q2 disappoints, gearing up for strong H2FY15E
Cipla Q2 disappoints, gearing up for strong H2FY15E
 
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; HoldHSIL Q4FY15: Disappointing growth but margins maintained; Hold
HSIL Q4FY15: Disappointing growth but margins maintained; Hold
 
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 PI Industries: Another strong performance; Sales up 16% in Q1FY15 PI Industries: Another strong performance; Sales up 16% in Q1FY15
PI Industries: Another strong performance; Sales up 16% in Q1FY15
 
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buyJK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
JK Lakshmi Cement Q4FY15: Attractive valuations; Maintain buy
 
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas LilladherKSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
KSB Pumps Q3CY14 Result Update: Weak margin performance - Prabhudas Lilladher
 
Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610Bayer india ru4qfy2010-020610
Bayer india ru4qfy2010-020610
 
Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270Stock Tip: Buy this stock for a target of Rs270
Stock Tip: Buy this stock for a target of Rs270
 
Long term investment: Buy Bharat Forge for target price of Rs1220
Long term investment: Buy Bharat Forge for target price of Rs1220Long term investment: Buy Bharat Forge for target price of Rs1220
Long term investment: Buy Bharat Forge for target price of Rs1220
 
Dhanuka Agritech's FY15 net profit up 14%; Buy
Dhanuka Agritech's FY15 net profit up 14%; BuyDhanuka Agritech's FY15 net profit up 14%; Buy
Dhanuka Agritech's FY15 net profit up 14%; Buy
 
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
Alembic Pharma Q1FY15: EBITDA margins improved by ~285 bps y-o-y; Hold
 
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil FinanceQ2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
Q2FY15: Hold Federal Bank for a target of Rs156 - Sushil Finance
 
ENIL 1QFY18
ENIL 1QFY18ENIL 1QFY18
ENIL 1QFY18
 
Q2FY23_Results-Presentation.pdf
Q2FY23_Results-Presentation.pdfQ2FY23_Results-Presentation.pdf
Q2FY23_Results-Presentation.pdf
 
ING Vyasa Bank Q2FY14 Result: Maintain neutral
ING Vyasa Bank Q2FY14 Result: Maintain neutralING Vyasa Bank Q2FY14 Result: Maintain neutral
ING Vyasa Bank Q2FY14 Result: Maintain neutral
 
HGSL 1QFY18
HGSL 1QFY18HGSL 1QFY18
HGSL 1QFY18
 
Mindtree 1QFY18
Mindtree 1QFY18Mindtree 1QFY18
Mindtree 1QFY18
 
Ashok Leyland
Ashok LeylandAshok Leyland
Ashok Leyland
 
Investor-presentation-FY-22-23-FV-24-05.pdf
Investor-presentation-FY-22-23-FV-24-05.pdfInvestor-presentation-FY-22-23-FV-24-05.pdf
Investor-presentation-FY-22-23-FV-24-05.pdf
 
Entertainment Network Ltd: Stock Price & Q4 Results Of Entertainment Network ...
Entertainment Network Ltd: Stock Price & Q4 Results Of Entertainment Network ...Entertainment Network Ltd: Stock Price & Q4 Results Of Entertainment Network ...
Entertainment Network Ltd: Stock Price & Q4 Results Of Entertainment Network ...
 
Hindustan Zinc: Still lot of juice left; buy
Hindustan Zinc: Still lot of juice left; buyHindustan Zinc: Still lot of juice left; buy
Hindustan Zinc: Still lot of juice left; buy
 

Mehr von IndiaNotes.com

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
IndiaNotes.com
 
Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15
IndiaNotes.com
 
Fce sqs india_29_jul15
Fce sqs india_29_jul15Fce sqs india_29_jul15
Fce sqs india_29_jul15
IndiaNotes.com
 

Mehr von IndiaNotes.com (20)

Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15Fce glaxo smithkline_12aug15
Fce glaxo smithkline_12aug15
 
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across IndiaGSK Consumer: Horlicks strengthens its position as No.1 brand across India
GSK Consumer: Horlicks strengthens its position as No.1 brand across India
 
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccinesHester Biosciences gets manufacturing licence for 2 additional poultry vaccines
Hester Biosciences gets manufacturing licence for 2 additional poultry vaccines
 
Cummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debtCummins India: No interest burden being free from long-term or short-term debt
Cummins India: No interest burden being free from long-term or short-term debt
 
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
Buy Makers Laboratories, company growing rapidly with strong thrust on brande...
 
Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...Buy Multibase India, globalisation of the auto component sector to benefit th...
Buy Multibase India, globalisation of the auto component sector to benefit th...
 
Capital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARECapital First: Long-term credit rating is rated highly at AA+ by CARE
Capital First: Long-term credit rating is rated highly at AA+ by CARE
 
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
Orient Cement: Best placed to benefit from demand revival in AP & Telengana r...
 
Canara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16ECanara Bank's operating performance to improve in remaining 9MFY16E
Canara Bank's operating performance to improve in remaining 9MFY16E
 
Nirmal lupin 06_aug15
Nirmal lupin 06_aug15Nirmal lupin 06_aug15
Nirmal lupin 06_aug15
 
Hexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, BuyHexaware Technologies adds 9 clients in Q2CY15, Buy
Hexaware Technologies adds 9 clients in Q2CY15, Buy
 
Fce thermax 31_jul15
Fce thermax 31_jul15Fce thermax 31_jul15
Fce thermax 31_jul15
 
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; BuyPI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
PI Industries: Custom synthesis exports deliver growth of ~26% in Q1FY16; Buy
 
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price targetTorrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
Torrent Pharma Q1FY16: IndiaNivesh maintain 'buy' for an upgraded price target
 
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
IndiaNivesh maintain 'buy' on this textile scrip with upgraded target after Q...
 
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; BuyAgro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
Agro Tech Foods: Demonstrates continued strong growth in tough environment; Buy
 
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declinesATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
ATS Research positive on Deepak Nitrate, buy at CMP and further add on declines
 
Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15Firstcall can fin_homes_ltd_29_july15
Firstcall can fin_homes_ltd_29_july15
 
Fce sqs india_29_jul15
Fce sqs india_29_jul15Fce sqs india_29_jul15
Fce sqs india_29_jul15
 
Nb maxwell 29_july15
Nb  maxwell 29_july15Nb  maxwell 29_july15
Nb maxwell 29_july15
 

Kürzlich hochgeladen

MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdfMASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
Cocity Enterprises
 
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdfFOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
Cocity Enterprises
 
Economics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjwEconomics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjw
mordockmatt25
 
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnLaw of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
TintoTom3
 
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadhabortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
samsungultra782445
 
abortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammam
abortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammamabortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammam
abortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammam
samsungultra782445
 

Kürzlich hochgeladen (20)

劳伦森大学毕业证
劳伦森大学毕业证劳伦森大学毕业证
劳伦森大学毕业证
 
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
Famous Kala Jadu, Black magic expert in Faisalabad and Kala ilam specialist i...
 
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budgetCall Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
Call Girls Howrah ( 8250092165 ) Cheap rates call girls | Get low budget
 
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
20240419-SMC-submission-Annual-Superannuation-Performance-Test-–-design-optio...
 
Explore Dual Citizenship in Africa | Citizenship Benefits & Requirements
Explore Dual Citizenship in Africa | Citizenship Benefits & RequirementsExplore Dual Citizenship in Africa | Citizenship Benefits & Requirements
Explore Dual Citizenship in Africa | Citizenship Benefits & Requirements
 
Collecting banker, Capacity of collecting Banker, conditions under section 13...
Collecting banker, Capacity of collecting Banker, conditions under section 13...Collecting banker, Capacity of collecting Banker, conditions under section 13...
Collecting banker, Capacity of collecting Banker, conditions under section 13...
 
Toronto dominion bank investor presentation.pdf
Toronto dominion bank investor presentation.pdfToronto dominion bank investor presentation.pdf
Toronto dominion bank investor presentation.pdf
 
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdfMASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
MASTERING FOREX: STRATEGIES FOR SUCCESS.pdf
 
fundamentals of corporate finance 11th canadian edition test bank.docx
fundamentals of corporate finance 11th canadian edition test bank.docxfundamentals of corporate finance 11th canadian edition test bank.docx
fundamentals of corporate finance 11th canadian edition test bank.docx
 
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdfFOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
FOREX FUNDAMENTALS: A BEGINNER'S GUIDE.pdf
 
Pension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdfPension dashboards forum 1 May 2024 (1).pdf
Pension dashboards forum 1 May 2024 (1).pdf
 
Business Principles, Tools, and Techniques in Participating in Various Types...
Business Principles, Tools, and Techniques  in Participating in Various Types...Business Principles, Tools, and Techniques  in Participating in Various Types...
Business Principles, Tools, and Techniques in Participating in Various Types...
 
Economics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjwEconomics Presentation-2.pdf xxjshshsjsjsjwjw
Economics Presentation-2.pdf xxjshshsjsjsjwjw
 
Lion One Corporate Presentation May 2024
Lion One Corporate Presentation May 2024Lion One Corporate Presentation May 2024
Lion One Corporate Presentation May 2024
 
W.D. Gann Theory Complete Information.pdf
W.D. Gann Theory Complete Information.pdfW.D. Gann Theory Complete Information.pdf
W.D. Gann Theory Complete Information.pdf
 
uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...
uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...
uk-no 1 kala ilam expert specialist in uk and qatar kala ilam expert speciali...
 
Technology industry / Finnish economic outlook
Technology industry / Finnish economic outlookTechnology industry / Finnish economic outlook
Technology industry / Finnish economic outlook
 
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnLaw of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
Law of Demand.pptxnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnnn
 
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadhabortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
abortion pills in Jeddah Saudi Arabia (+919707899604)cytotec pills in Riyadh
 
abortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammam
abortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammamabortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammam
abortion pills in Riyadh Saudi Arabia (+919707899604)cytotec pills in dammam
 

Balkrishna Industries Q4FY14 results better than estimates, buy - Prabhudas Lilladher

  • 1.     Balkrishna Industries  Results above estimates; outlook encouraging May 20, 2014  PrabhudasLilladher Pvt. Ltd. and/or its associates (the 'Firm') does and/or seeks to do business with companies covered in its research reports. As a result investors should be aware that the  Firm may have a conflict of interest that could affect the objectivity of the report. Investors should consider this report as only a single factor in making their investment decision.  Please refer to important disclosures and disclaimers at the end of the report    Q4FY14 Result Update  Surjit Arora  surjitarora@plindia.com  +91‐22‐66322235  Hussain Kagzi  hussainkagzi@plindia.com  +91‐22‐66322242  Rating  Accumulate  Price  Rs568  Target Price  Rs630   Implied Upside   10.9%  Sensex   24,377  Nifty  7,276  (Prices as on May 20, 2014)  Trading data  Market Cap. (Rs bn)  54.9  Shares o/s (m)  96.7  3M Avg. Daily value (Rs m)  174.2  Major shareholders  Promoters  58.30%  Foreign  11.00%  Domestic Inst.  16.74%  Public & Other   13.96%  Stock Performance  (%)  1M  6M  12M  Absolute  12.2  100.8  109.3  Relative   4.5  82.7  88.8  How we differ from Consensus  EPS (Rs)  PL  Cons.  % Diff.  2015  57.6  56.1  2.7  2016  66.3  64.1  3.4    Price Performance (RIC: BLKI.BO, BB: BIL IN)    Source: Bloomberg  100 200 300 400 500 600 700 May‐13 Jul‐13 Sep‐13 Nov‐13 Jan‐14 Mar‐14 May‐14 (Rs) Balkrishna  Industries  (BIL’s)  Q4FY14  operating  performance  was  better  than  our  estimate on account of higher than expected volume growth at 19.8% during the  quarter.  Strong  topline  led  to  a  450bps  YoY  improvement  in  EBITDA  margins  to  25.8%  with  EBITDA  for  the  quarter  increasing  by  61.5%  YoY  to  Rs2.68bn  (PLe‐ Rs2.52bn). Given the strong balance sheet, with ROEs in excess of 20% and strong  free  cash  flow  in  FY15E  and  FY16E,  we  maintain  our  ‘Accumulate’  rating  on  the  stock. The stock is currently trading at 5.6x FY16E EV/EBITDA and 8.6x FY16E EPS,  at a ~26% discount to Titan International. Given the superior ROEs and earnings  CAGR of ~15.0%, we assign a 1yr fwd P/E multiple of 9.5x FY16E earnings (@ 20%  discount to Titan International) to arrive at our TP of Rs630/share.       Adj.  Profit  grew  by  85.6%  YoY  led  by  strong  operational  performance:  BIL  reported a growth of 33.0% in its top‐line at Rs10.4bn (PLe: Rs10.0bn), mainly  on account of 19.8% increase in volume to 40,823 tonnes. Recipe cost/kg in the  current quarter declined by 5.5% YoY to Rs118.5/kg on account of lower natural  rubber cost. As a result, raw material/sales ratio declined by 800bps YoY. This  was  partially  negated  by  390bps  YoY  increase  in  other  expenses.  As  a  result,  EBITDA  margins  expanded  by  450bps  to  25.8%.  This  resulted  in  a  61.5%  YoY  increase  in  EBITDA  to  Rs2.7bn  (PLe‐Rs2.5bn).  On  account  of  strong  operating  performance,  PAT  grew  by  85.6%  YoY  to  Rs1.5bn  ahead  of  our  estimate  of  Rs1.3bn.  Contd…2        Key financials (Y/e March)        2013 2014  2015E 2016E Revenues (Rs m)  31,906 35,767  41,375 48,326      Growth (%)  13.1 12.1  15.7 16.8 EBITDA (Rs m)  6,645 8,937  10,534 12,235 PAT (Rs m)  3,559 4,877  5,571 6,409 EPS (Rs)  36.8 50.5  57.6 66.3      Growth (%)  32.5 37.0  14.2 15.0 Net DPS (Rs)  1.6 2.0  3.0 4.0   Profitability & Valuation        2013 2014  2015E 2016E EBITDA margin (%)  20.8 25.0  25.5 25.3 RoE (%)  28.5 29.5  25.8 23.3 RoCE (%)  11.8 12.9  13.2 14.6 EV / sales (x)  2.3 2.2  1.8 1.4 EV / EBITDA (x)  11.0 8.9  7.2 5.6 PE (x)  15.4 11.3  9.9 8.6 P / BV (x)  3.9 2.9  2.3 1.8 Net dividend yield (%)  0.3 0.4  0.5 0.7 Source: Company Data; PL Research 
  • 2.     May 20, 2014  2   Balkrishna Industries   Concall highlights – Refinancing of ECBs to save Rs100‐120m of interest cost:  Management indicated refinancing of $100m ECB at LIBOR + 20bps, whereas the  $175mn  ECB  has  been  refinanced  at  a  lower  rate  at  2.1‐2.2%  as  against  3%  earlier. The above would lead to a savings in the interest cost to the tune of  Rs100‐120m/ year. Management maintained its volume guidance of 160,000 –  165,000  MT  for  FY15E  and  200,000  MT  for  FY16E.  Management  sounded  positive  on  the  demand  outlook  for  both,  agricultural  as  well  as  industrial  segment (construction and mining) across geographies.    Euro revenues hedged at Rs87/€ in FY15E as against Rs75/€ in FY14: BIL have  locked in an average rate of Rs87/€ for FY15 as against Rs75/€ in FY14. Hence,  the  recent  currency  appreciation  (Rs80/€)  would  not  have  any  impact  on  the  profitability of the company. At the same time, on account of correction in the  raw material prices (esp. Natural Rubber), they have taken a price cut of 4‐5% in  Apr’14.  Despite  this,  management  sounded  confident  on  maintaining  the  EBITDA  margins  at  25‐26%  range  as  they  would  enjoy  higher  realisations  on  account of currency hedges.   Outlook  and  Valuation:  Balakrishna  Industries  (BIL)  has  built  a  substantive  export  business  in  off‐highway‐tyres  (OHT),  a  niche  area,  where  it  enjoys  a  global market share of ~4%. BKT generates 90% of its revenues from exports. By  offering an extensive variety of OHTs (2,000+ SKUs) at prices 25‐30% lower than  the  global  majors  (Michelin,  Bridgestone),  BKT  has  leveraged  India’s  low‐cost  manufacturing  capabilities  to  a  great  effect.  Given  the  strong  balance  sheet,  with ROEs in excess of 20% and strong free cash flow in FY15E and FY16E, we  maintain our ‘Accumulate’ rating on the stock. The stock is currently trading at  5.6x  FY16E  EV/EBITDA  and  8.6x  FY16E  EPS,  at  a  ~26%  discount  to  Titan  International.    
  • 3.     May 20, 2014  3   Balkrishna Industries  Exhibit 1: Q4FY14 Result Overview (Rs m)  Y/e March  Q4FY14 Q4FY13 YoY gr. (%) Q3FY14 FY14  FY13 YoY gr. (%) Net Sales      10,306          7,740             (1.6)        8,673      35,357      31,731            11.4  Other Operating Income              62                53          182.5            171            410            175          134.5  Total      10,368          7,793            33.0         8,844      35,767      31,906            12.1  Expenditure                 Raw Material          4,839          4,273          (12.9)        4,104      17,210      17,910             (3.9)   % of Net Sales          46.9            55.2            47.3          48.7          56.4    Salaries & Wages            407             314            55.9            360         1,386         1,075            28.9    % of Net Sales             3.9              4.1               4.2             3.9             3.4    Power and Fuel            331             262              5.5           285         1,170         1,153              1.4    % of Net Sales             3.2              3.4               3.3             3.3             3.6    Other Exp.         2,113          1,285          (11.4)        1,806         7,064         5,124            37.9    % of Net Sales          20.5            16.6            20.8          20.0          16.1    Total Expenditure         7,690          6,134           6,555      26,830      25,262    EBITDA         2,679          1,659            61.5         2,289         8,938         6,644            34.5    EBITDA Margin (%)          25.8            21.3            26.4          25.0          20.8    Depreciation            479             321            49.0            425         1,650         1,077            53.2  Net Exchange Difference (Gain)/Loss             (21)             (32)                 ‐              (5)              57    Net interest              99                35          185.1              59            255            200            27.7  Non Operative Income              31                11          193.4              52            138              42          229.5  Exceptional                 PBT         2,153          1,345            60.0         1,857         7,175         5,352            34.1  Tax Total            611             494            23.7            619         2,293         1,794            27.9    Tax Rate‐Total (%)  28.4 36.7   33.3 32.0  33.5   Rep.PAT         1,542             851            81.1         1,238         4,882         3,558            37.2  Extraordinary Expenses             (21)             (32)                 ‐              (5)              57    Adj. profit         1,521             819            85.6         1,238         4,877         3,615            34.9  Operating Metrics  Sale Tonnage (MT)      40,823        34,061            19.9      33,901    142,810    138,339              3.2  Realisation in Rs per Kg            254             227            11.8            261            250            231              8.6  Recipe (RM) cost in Rs per Kg            119             125             (5.5)           121            121            129             (6.9) EBITDA per kg              66                49            34.7              68              63              48            30.3  Source: xxx     
  • 4.     May 20, 2014  4   Balkrishna Industries  Income Statement (Rs m)            Y/e March       2013  2014  2015E 2016E Net Revenue  31,906  35,767  41,375 48,326 Raw Material Expenses  17,910  17,210  20,256 23,770 Gross Profit  13,996  18,557  21,119 24,556 Employee Cost  1,075  1,386  1,597 1,831 Other Expenses  6,277  8,234  8,988 10,490 EBITDA  6,645  8,937  10,534 12,235 Depr. & Amortization  1,077  1,650  2,100 2,500 Net Interest  200  255  420 500 Other Income  42  138  300 330 Profit before Tax  5,410  7,170  8,314 9,565 Total Tax  1,794  2,293  2,744 3,156 Profit after Tax  3,617  4,877  5,571 6,409 Ex‐Od items / Min. Int.  (57)  10  — — Adj. PAT  3,559  4,877  5,571 6,409 Avg. Shares O/S (m)  96.7  96.7  96.7 96.7 EPS (Rs.)  36.8  50.5  57.6 66.3   Cash Flow Abstract (Rs m)     Y/e March       2013  2014  2015E 2016E C/F from Operations  5,501  5,111  6,525 6,812 C/F from Investing  (9,594)  (7,277)  (2,000) (500) C/F from Financing  3,181  (399)  (3,996) (3,606) Inc. / Dec. in Cash  (911)  (2,564)  529 2,705 Opening Cash  3,574  2,663  99 627 Closing Cash  2,663  99  627 3,333 FCFF  (164)  1,256  1,522 3,316 FCFE  3,848  5,086  (1,978) (1,184)       Key Financial Metrics  Y/e March       2013  2014  2015E 2016E Growth      Revenue (%)  13.1  12.1  15.7 16.8 EBITDA (%)  31.3  34.5  17.9 16.1 PAT (%)  32.5  37.0  14.2 15.0 EPS (%)  32.5  37.0  14.2 15.0 Profitability      EBITDA Margin (%)  20.8  25.0  25.5 25.3 PAT Margin (%)  11.2  13.6  13.5 13.3 RoCE (%)  11.8  12.9  13.2 14.6 RoE (%)  28.5  29.5  25.8 23.3 Balance Sheet      Net Debt : Equity  1.3  1.3  0.8 0.4 Net Wrkng Cap. (days)  78  89  79 80 Valuation      PER (x)  15.4  11.3  9.9 8.6 P / B (x)  3.9  2.9  2.3 1.8 EV / EBITDA (x)  11.0  8.9  7.2 5.6 EV / Sales (x)  2.3  2.2  1.8 1.4 Earnings Quality      Eff. Tax Rate  33.2  32.0  33.0 33.0 Other Inc / PBT  0.8  1.9  3.6 3.5 Eff. Depr. Rate (%)  6.0  7.6  8.0 8.2 FCFE / PAT  108.1  104.3  (35.5) (18.5) Source: Company Data, PL Research.        Balance Sheet Abstract (Rs m)    Y/e March       2013  2014  2015E 2016E Shareholder's Funds  14,190  18,826  24,304 30,602 Total Debt  20,744  24,574  21,074 16,574 Other Liabilities  999  1,000  1,100 1,100 Total Liabilities  35,932  44,400  46,478 48,276 Net Fixed Assets  22,232  28,058  27,958 25,458 Goodwill  —  —  — — Investments  329  4,265  4,265 4,265 Net Current Assets  13,370  12,077  14,255 18,553      Cash & Equivalents  2,663  98  628 3,333      Other Current Assets  15,228  16,320  18,218 20,469      Current Liabilities  4,520  4,341  4,591 5,249 Other Assets  —  —  — — Total Assets  35,932  44,400  46,478 48,276         Quarterly Financials (Rs m)      Y/e March      Q1FY14  Q2FY14  Q3FY14 Q4FY14 Net Revenue  8,159  8,396  8,844 10,368 EBITDA  1,787  2,024  2,289 2,679 % of revenue  21.9  24.1  25.9 25.8 Depr. & Amortization  353  393  425 479 Net Interest  (128)  5  7 68 Other Income  171  44  52 31 Profit before Tax  1,548  1,619  1,857 2,153 Total Tax  524  524  619 611 Profit after Tax  1,024  1,095  1,238 1,542 Adj. PAT  1,038  1,095  1,238 1,521 Source: Company Data, PL Research.   
  • 5.     May 20, 2014  5   Balkrishna Industries            Prabhudas Lilladher Pvt. Ltd.  3rd Floor, Sadhana House, 570, P. B. Marg, Worli, Mumbai‐400 018, India  Tel: (91 22) 6632 2222 Fax: (91 22) 6632 2209  Rating Distribution of Research Coverage    26.2% 52.4% 21.4% 0.0% 0% 10% 20% 30% 40% 50% 60% BUY Accumulate Reduce Sell % of Total Coverage   PL’s Recommendation Nomenclature      BUY   :  Over 15% Outperformance to Sensex over 12‐months  Accumulate  :  Outperformance to Sensex over 12‐months  Reduce  :  Underperformance to Sensex over 12‐months  Sell  :  Over 15% underperformance to Sensex over 12‐months  Trading Buy  :  Over 10% absolute upside in 1‐month  Trading Sell  :  Over 10% absolute decline in 1‐month  Not Rated (NR)  :  No specific call on the stock  Under Review (UR)  :  Rating likely to change shortly  This  document  has  been  prepared  by  the  Research  Division  of  Prabhudas  Lilladher  Pvt.  Ltd.  Mumbai,  India  (PL)  and  is  meant  for  use  by  the  recipient  only  as  information and is not for circulation.  This document is not to be reported or copied or made available to others without prior permission of PL. It should not be  considered or taken as an offer to sell or a solicitation to buy or sell any security.  The information contained in this report has been obtained from sources that are considered to be reliable. However, PL has not independently verified the accuracy  or completeness of the same. Neither PL nor any of its affiliates, its directors or its employees accept any responsibility of whatsoever nature for the information,  statements and opinion given, made available or expressed herein or for any omission therein.  Recipients of this report should be aware that past performance is not necessarily a guide to future performance and value of investments can go down as well. The  suitability  or  otherwise  of  any  investments  will  depend  upon  the  recipient's  particular  circumstances  and,  in  case  of  doubt,  advice  should  be  sought  from  an  independent expert/advisor.  Either PL or its affiliates or its directors or its employees or its representatives or its clients or their relatives may have position(s), make market, act as principal or  engage in transactions of securities of companies referred to in this report and they may have used the research material prior to publication.  We may from time to time solicit or perform investment banking or other services for any company mentioned in this document.